ArticleClinical rheumatology2026
Risk factors for disease progression in primary Sjögren's syndrome patients with low disease activity: a multicenter registry-based cohort study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
objectivesPrimary Sjögren's syndrome (pSS) patients with low disease activity remain at risk for disease progression, yet predictive factors are poorly understood. We aimed to identify risk factors for disease worsening in pSS patients with initially low disease activity.
methodsWe conducted a registry-based cohort study using prospectively collected data from the Chinese Rheumatism Data Center (CRDC). Patients with pSS meeting either 2002 AECG or 2016 ACR/EULAR classification criteria and baseline ESSDAI < 5 were included. Disease worsening was defined as ESSDAI increase ≥ 3 points during follow-up. Cox proportional hazards regression with LASSO selection identified independent risk factors.
resultsAmong 745 patients (median age 46 years, 97.4% female), 214 (28.7%) experienced disease worsening during median follow-up of 36 months. Univariate analysis and LASSO regression selected 11 variables for multivariate analysis. Independent risk factors were renal involvement (HR = 6.18, 95%CI: 2.44-15.61, P < 0.001), anti-Sm positivity (HR = 2.10, 95%CI: 1.12-3.93, P = 0.020), and dry eye symptoms (HR = 1.46, 95%CI: 1.06-2.00, P = 0.022).
conclusionsNearly one-third of pSS patients with low disease activity experience disease worsening. Renal involvement, anti-Sm antibodies, and dry eye symptoms independently predict progression. Risk stratification based on these factors can identify patients requiring closer monitoring and potentially more intensive therapeutic intervention. Key Points • This multicenter registry study of 745 primary Sjögren's syndrome patients with low disease activity found that 28.7% experienced disease worsening during follow-up, highlighting that low disease activity does not guarantee disease stability. • Three independent predictors of disease progression were identified: renal involvement (HR = 6.18), anti-Sm antibody positivity (HR = 2.10), and dry eye symptoms (HR = 1.46). • Conventional synthetic DMARDs were not significantly associated with reduced disease worsening in adjusted models, highlighting the need for randomized trials to properly evaluate therapeutic strategies.
Indexed as
Identifiers
41563697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.